MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.Please visit mannkindcorp.com to learn more.